Praxis精密药品将在里斯本举行的2025年IEC2025上展示12项癫痫病管道更新，包括RECIANT结果

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming International Epilepsy Congress (IEC), taking place August 30–September 3, 2025, in Lisbon, Portugal.

In addition to showcasing recent topline results from the RADIANT study in focal onset seizures (FOS), Praxis will share the latest preclinical and clinical data and progress on trials across its precision epilepsy pipeline over twelve presentations at the event:

• Vormatrigine: Showcasing positive topline RADIANT results in FOS, updates from the first-in-human Phase 1 study, and further preclinical and clinical data supporting the accelerated advancement of the POWER1 pivotal study and the wider ENERGY program, poised to transform the epilepsy landscape.
• Relutrigine: Sharing the latest from the EMBOLD study in SCN2A- and SCN8A-DEE, the EMERALD registrational study in broad DEEs, as well as preclinical data emphasizing the promising potential of relutrigine to address significant unmet needs across the spectrum of DEEs.
• Elsunersen: Highlighting the ongoing EMBRAVE3 registrational study, alongside updates from the global emergency use cases demonstrating potential for long-term benefits, consistent safety and tolerability, and potential for further enhancement by precision sodium channel modulation in patients with early onset SCN2A gain-of-function DEE.